Reducing Episodic Cluster Headaches: Focus on Galcanezumab

Lanfranco Pellesi, Roberto De Icco, Mohammad Al-Mahdi Al-Karagholi, Messoud Ashina

Research output: Contribution to journalReview articlepeer-review


The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.

Original languageEnglish
Pages (from-to)1591-1599
Number of pages9
JournalJournal of Pain Research
Publication statusPublished - 2020


Dive into the research topics of 'Reducing Episodic Cluster Headaches: Focus on Galcanezumab'. Together they form a unique fingerprint.

Cite this